Literature DB >> 30847759

Beneluxa: What are the Prospects for Collective Bargaining on Pharmaceutical Prices Given Diverse Health Technology Assessment Processes?

James F O'Mahony1.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 30847759     DOI： 10.1007/s40273-019-00781-w

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  8 in total

1.  The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland's Health System?

Authors:  James F O'Mahony; Diarmuid Coughlan
Journal:  Pharmacoeconomics       Date:  2016-01       Impact factor: 4.981

2.  HIQA's CEA of Breast Screening: Pragmatic Policy Recommendations are Welcome, but ACERs Reported as ICERs are Not.

Authors:  James F O'Mahony; Charles Normand
Journal:  Value Health       Date:  2015-10-21       Impact factor: 5.725

3.  HIQA's Perspective on the Challenges Posed by Evaluations of Screening Programs: A Reply.

Authors:  James F O'Mahony
Journal:  Value Health       Date:  2018-08-23       Impact factor: 5.725

4.  Surveying the Cost-Effectiveness of the 20 Procedures with the Largest Public Health Services Waiting Lists in Ireland: Implications for Ireland's Cost-Effectiveness Threshold.

Authors:  Tse Chiang Chen; Dane Wanniarachige; Síofra Murphy; Katie Lockhart; James O'Mahony
Journal:  Value Health       Date:  2018-06-12       Impact factor: 5.725

5.  From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare.

Authors:  Matthijs Versteegh; Saskia Knies; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

6.  Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System.

Authors:  Laura Catherine Edney; Hossein Haji Ali Afzali; Terence Chai Cheng; Jonathan Karnon
Journal:  Pharmacoeconomics       Date:  2018-02       Impact factor: 4.981

7.  Cost-effectiveness of population-based screening for colorectal cancer.

Authors:  J F O'Mahony
Journal:  Br J Cancer       Date:  2013-02-07       Impact factor: 7.640

Review 8.  Discounting in Economic Evaluations.

Authors:  Arthur E Attema; Werner B F Brouwer; Karl Claxton
Journal:  Pharmacoeconomics       Date:  2018-07       Impact factor: 4.981
  8 in total
  4 in total

1.  Four Aspects Affecting Health Economic Decision Models and Their Validation.

Authors:  Talitha Feenstra; Isaac Corro-Ramos; Dominique Hamerlijnck; George van Voorn; Salah Ghabri
Journal:  Pharmacoeconomics       Date:  2021-12-16       Impact factor: 4.981

2.  Transferability of Economic Evaluations of Treatments for Advanced Melanoma.

Authors:  Claire Gorry; Laura McCullagh; Michael Barry
Journal:  Pharmacoeconomics       Date:  2020-02       Impact factor: 4.981

3.  Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.

Authors:  Brian Godman; Magdalene Wladysiuk; Stuart McTaggart; Amanj Kurdi; Eleonora Allocati; Mihajlo Jakovljevic; Francis Kalemeera; Iris Hoxha; Anna Nachtnebel; Robert Sauermann; Manfred Hinteregger; Vanda Marković-Peković; Biljana Tubic; Guenka Petrova; Konstantin Tachkov; Juraj Slabý; Radka Nejezchlebova; Iva Selke Krulichová; Ott Laius; Gisbert Selke; Irene Langner; András Harsanyi; András Inotai; Arianit Jakupi; Svens Henkuzens; Kristina Garuolienė; Jolanta Gulbinovič; Patricia Vella Bonanno; Jakub Rutkowski; Skule Ingeberg; Øyvind Melien; Ileana Mardare; Jurij Fürst; Sean MacBride-Stewart; Carol Holmes; Caridad Pontes; Corinne Zara; Marta Turu Pedrola; Mikael Hoffmann; Vasileios Kourafalos; Alice Pisana; Rita Banzi; Stephen Campbell; Bjorn Wettermark
Journal:  Biomed Res Int       Date:  2021-10-11       Impact factor: 3.411

4.  The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future.

Authors:  Brian Godman; Mainul Haque; Trudy Leong; Eleonora Allocati; Santosh Kumar; Salequl Islam; Jaykaran Charan; Farhana Akter; Amanj Kurdi; Carlos Vassalo; Muhammed Abu Bakar; Sagir Abdur Rahim; Nusrat Sultana; Farzana Deeba; M A Halim Khan; A B M Muksudul Alam; Iffat Jahan; Zubair Mahmood Kamal; Humaira Hasin; Shamsun Nahar; Monami Haque; Siddhartha Dutta; Jha Pallavi Abhayanand; Rimple Jeet Kaur; Godfrey Mutashambara Rwegerera; Renata Cristina Rezende Macedo do Nascimento; Isabella Piassi Dias Godói; Mohammed Irfan; Adefolarin A Amu; Patrick Matowa; Joseph Acolatse; Robert Incoom; Israel Abebrese Sefah; Jitendra Acharya; Sylvia Opanga; Lisper Wangeci Njeri; David Kimonge; Hye-Young Kwon; SeungJin Bae; Karen Koh Pek Khuan; Abdullahi Rabiu Abubakar; Ibrahim Haruna Sani; Tanveer Ahmed Khan; Shahzad Hussain; Zikria Saleem; Oliver Ombeva Malande; Thereza Piloya-Were; Rosana Gambogi; Carla Hernandez Ortiz; Luke Alutuli; Aubrey Chichonyi Kalungia; Iris Hoxha; Vanda Marković-Peković; Biljana Tubic; Guenka Petrova; Konstantin Tachkov; Ott Laius; András Harsanyi; András Inotai; Arianit Jakupi; Svens Henkuzens; Kristina Garuoliene; Jolanta Gulbinovič; Magdalene Wladysiuk; Jakub Rutkowski; Ileana Mardare; Jurij Fürst; Stuart McTaggart; Sean MacBride-Stewart; Caridad Pontes; Corinne Zara; Eunice Twumwaa Tagoe; Rita Banzi; Janney Wale; Mihajlo Jakovljevic
Journal:  Front Public Health       Date:  2021-06-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.